NSE · AHCL · Chemicals
Anlon Healthcare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹55 Cr with net profit ₹10 Cr — a 17.67% net margin, versus 14.47% the period before.
Shareholding
As of 2026-06-30
- Promoter52.68%
- Public44.43%
- FII1.67%
- DII1.22%
34,671 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.9× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Chemicals · ranked #65 of 159 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Pidilite Industries Ltd. | ₹1,65,887 Cr | 286.45 | 15.31 | 22.61% | 16.77% |
| Solar Industries India Ltd. | ₹1,63,606 Cr | 298.74 | 26.07 | 26.72% | 17.05% |
| SRF Ltd. | ₹78,369 Cr | 134.68 | 5.58 | 13.07% | 11.9% |
| Linde India Limited | ₹57,332 Cr | 740.36 | 13.44 | 12.48% | 0.18% |
| Gujarat Fluorochemicals Ltd. | ₹50,334 Cr | 461.91 | 6.45 | 7.3% | 11.49% |
| Godrej Industries Ltd. | ₹43,559 Cr | 98.05 | 3.9 | 11.1% | 5.58% |
| Navin Fluorine International Ltd. | ₹38,957 Cr | 183.04 | 9.79 | 16.69% | 20.02% |
| Himadri Speciality Chem Limited | ₹38,845 Cr | 193.44 | 8.25 | 15.96% | 16.12% |
| Deepak Nitrite Ltd. | ₹22,840 Cr | 103.95 | 3.91 | 9.43% | 6.98% |
| Deepak Fertilisers & Petrochemicals Corp Ltd. | ₹20,530 Cr | 147.31 | 3 | 10.77% | 6.41% |
| Anlon Healthcare Limited(this company) | ₹844 Cr | 6.82 | 0.37 | 12.39% | 23.86% |
AI analysis
AI-generated · google/gemini-2.5-flashAnlon Healthcare Limited (AHCL) is listed in the Chemicals sector with a market capitalization of Rs 817 Cr. The company reported an EPS of 0.54 and a PE ratio of 28.46. Its book value stands at 4.33, with a Return on Equity (ROE) of 12.39% and a Return on Capital Employed (ROCE) of 16.89%. The debt-to-equity ratio is 1.46. For the quarter ended March 2026, the company recorded revenue of Rs 50.89 Cr and a net profit of Rs 10.5 Cr.
Positives
- +The Return on Capital Employed (ROCE) was 16.89%, indicating efficient use of capital.
- +Promoter shareholding in March 2026 was 52.68%, representing a majority stake.
- +No shares were pledged by promoters, with promoter pledge at 0%.
Negatives
- −The profit margin is 0%, indicating no profitability from operations based on the provided figure.
- −The debt-to-equity ratio is 1.46, which is relatively high.
- −Promoter shareholding significantly decreased from 70.26% in October 2024 to 52.68% in March 2026.
- −The company reported a negative net profit of Rs -2.49 Cr in December 2024.
- −No dividend yield was reported (0%).
Financial Performance
In the financial year ending March 2025, Anlon Healthcare Limited reported total revenue of Rs 120.45 Cr and a net profit of Rs 20.52 Cr. Quarterly revenue for March 2026 was Rs 50.89 Cr, with a net profit of Rs 10.5 Cr. This follows a previous quarter in December 2025 where revenue was Rs 35.58 Cr and net profit was Rs 5.15 Cr.
Profitability & Returns
The company's Return on Equity (ROE) is 12.39%, while the Return on Capital Employed (ROCE) is 16.89%. The earnings per share (EPS) for the most recent available annual period (Mar 2025) was Rs 6.37. The profit margin for the company is 0% based on the provided data.
Balance Sheet
Anlon Healthcare Limited has a debt-to-equity ratio of 1.46, indicating a significant reliance on debt financing. The book value per share is Rs 4.33. No further detailed balance sheet figures are available in the provided data.
Ownership & Pledges
Public shareholding stands at 42.40%. Total institutional holding is 4.92%. There are no promoter shares pledged, with promoter pledge at 0%.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.